- Home
- ZH vs GLUE Comparison
ZH vs GLUE Comparison
Compare ZH & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- GLUE
- Stock Information
- Founded
- ZH 2011
- GLUE 2019
- Country
- ZH China
- GLUE United States
- Employees
- ZH N/A
- GLUE N/A
- Industry
- ZH Business Services
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- GLUE Health Care
- Exchange
- ZH Nasdaq
- GLUE Nasdaq
- Market Cap
- ZH 365.1M
- GLUE 351.2M
- IPO Year
- ZH 2021
- GLUE 2021
- Fundamental
- Price
- ZH $4.81
- GLUE $4.80
- Analyst Decision
- ZH Strong Buy
- GLUE Buy
- Analyst Count
- ZH 1
- GLUE 2
- Target Price
- ZH $4.70
- GLUE $13.50
- AVG Volume (30 Days)
- ZH 390.5K
- GLUE 369.2K
- Earning Date
- ZH 08-27-2025
- GLUE 08-07-2025
- Dividend Yield
- ZH N/A
- GLUE N/A
- EPS Growth
- ZH N/A
- GLUE N/A
- EPS
- ZH 0.22
- GLUE 0.29
- Revenue
- ZH $439,821,184.00
- GLUE $177,986,000.00
- Revenue This Year
- ZH N/A
- GLUE $83.76
- Revenue Next Year
- ZH $7.46
- GLUE N/A
- P/E Ratio
- ZH $21.62
- GLUE $16.32
- Revenue Growth
- ZH N/A
- GLUE 2990.57
- 52 Week Low
- ZH $3.13
- GLUE $3.50
- 52 Week High
- ZH $6.32
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- ZH 56.37
- GLUE 51.69
- Support Level
- ZH $4.58
- GLUE $4.54
- Resistance Level
- ZH $5.01
- GLUE $4.93
- Average True Range (ATR)
- ZH 0.28
- GLUE 0.21
- MACD
- ZH 0.02
- GLUE 0.06
- Stochastic Oscillator
- ZH 55.91
- GLUE 81.43
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.